Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Apr;39(4):1254-7.
doi: 10.1128/JCM.39.4.1254-1257.2001.

Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples

S Cunningham  1 , B Ank, D Lewis, W Lu, M Wantman, J A Dileanis, J B Jackson, P Palumbo, P Krogstad, S H Eshleman
Affiliations
Clinical Trial

Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples

S Cunningham et al. J Clin Microbiol. 2001 Apr.

Abstract

The ViroSeq HIV-1 Genotyping System is a commercially available, integrated sequence-based system for analysis of human immunodeficiency virus type 1 (HIV-1) drug resistance. We evaluated the performance of this system by analyzing HIV-1 in pediatric plasma samples. Plasma samples from children 4 months to 17 years of age were obtained from a clinical trial protocol (PACTG 377). Children in PACTG 377 were randomized to four treatment arms, including different combinations of antiretroviral drugs. HIV-1 genotyping was performed using samples collected prior to antiretroviral therapy (baseline) and at the time of virologic failure. Performance of the genotyping system was compared in three university laboratories. A total of 196 samples were analyzed, including 135 baseline and 61 failure samples. Plasma volumes ranged from 0.05 to 0.5 ml, and viral loads ranged from 1,084 to 3,484,991 copies/ml. PCR products suitable for sequencing were obtained for 192 of the 196 samples. Complete sequences for protease and reverse transcriptase were obtained for all of these 192 samples. For 180 samples, data were obtained from both DNA strands for the entire region analyzed. There was no evidence of sample cross-contamination based on phylogenetic analysis of HIV-1 sequences. Performance of the genotyping system was similar in three laboratories. This genotyping system performs well for analysis of HIV-1 in pediatric plasma samples, including those with low volume and low viral load. The availability of this system should facilitate studies of HIV-1 drug resistance.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Orientation and position of PCR and sequencing primers. The position and orientation of primers in the ViroSeq HIV-1 Genotyping System are shown with respect to the protease and RT coding regions. The two PCR primers (PCR-F and PCR-R) and the seven sequencing primers are shown.
See this image and copyright information in PMC

References

    1. Colgrove R C, Pitt J, Chung P H, Welles S L, Japour A J. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS. 1998;12:2281–2288. - PubMed
    1. Dileanis J, Marlowe N, Hoo B, Brown R C, Bulmer M, Huang D, Palumbo P, Schuurman R, Van Laethem K, Vandamme A-M, Elbeik T. 5th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom. 2000. Performance of the new ViroSeq HIV-1 Genotyping System (version 2) with group M subtype panel and with subtype B clinical research samples at test sites.
    1. Frenkel L M, Wagner L E, Demeter L M, Dewhurst S, Coombs R W, Murante B L, Reichman R C. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321–1326. - PubMed
    1. Hecht F M, Grant R M, Petropoulos C J, Dillon B, Chesney M A, Hellmann N S, Bandrapalli N I, Digilio L, Branson B, Kahn J O. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–311. - PubMed
    1. Hirsch M S, Brun-Vezinet F, D'Aquila R, Hammer S M, Johnson V A, Kuritzkes D R, Loveday C, Mellors J W, Clotet B, Conway B, Demeter L M, Vella S, Jacobsen D M, Richman D D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society–USA panel. JAMA. 2000;283:2417–2426. - PubMed

MeSH terms